574,085 Shares in Oric Pharmaceuticals, Inc. $ORIC Purchased by Candriam S.C.A.

Candriam S.C.A. bought a new position in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 574,085 shares of the company’s stock, valued at approximately $7,274,000.

Several other institutional investors and hedge funds have also recently modified their holdings of ORIC. Federation des caisses Desjardins du Quebec boosted its position in shares of Oric Pharmaceuticals by 100.0% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock valued at $33,000 after acquiring an additional 2,000 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of Oric Pharmaceuticals by 184.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock worth $37,000 after purchasing an additional 2,936 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Oric Pharmaceuticals by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock worth $39,000 after purchasing an additional 977 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in Oric Pharmaceuticals in the third quarter valued at approximately $60,000. Finally, CANADA LIFE ASSURANCE Co purchased a new stake in Oric Pharmaceuticals in the third quarter valued at approximately $65,000. Hedge funds and other institutional investors own 95.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on ORIC. Weiss Ratings reissued a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Tuesday, April 21st. The Goldman Sachs Group upgraded shares of Oric Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $15.00 price objective on the stock in a research report on Friday, May 15th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Oric Pharmaceuticals in a report on Monday, June 8th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Oric Pharmaceuticals in a research report on Friday, May 22nd. Finally, Citigroup reduced their target price on Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $19.27.

Oric Pharmaceuticals Price Performance

Shares of ORIC opened at $10.85 on Monday. The firm has a market cap of $1.12 billion, a P/E ratio of -7.53 and a beta of 1.02. The stock has a 50 day simple moving average of $9.00 and a two-hundred day simple moving average of $10.13. Oric Pharmaceuticals, Inc. has a 1 year low of $7.23 and a 1 year high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). On average, equities analysts anticipate that Oric Pharmaceuticals, Inc. will post -1.45 earnings per share for the current year.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.